Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 4/2022

29.01.2022 | Regenerative Medicine (SM Wu, Section Editor)

Mesenchymal Stromal Cell Exosomes in Cardiac Repair

verfasst von: Darukeshwara Joladarashi, Raj Kishore

Erschienen in: Current Cardiology Reports | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of the Review

Mesenchymal stromal cells (MSCs) are considered an attractive option for cell-based therapy because of their immune-privileged phenotype and paracrine activity. Substantial preclinical evidence indicates that MSC exosomes recapitulate MSC cellular function in cardiac regeneration and repair. Therefore, in this review, we briefly discuss the latest research progress of MSC exosomes in cardiac repair and regeneration.

Recent Findings

The recent revolutionary advance in controlling the contents of the exosomes by manipulating parental cells through bioengineering methods to alter specific signaling pathways in ischemic myocardium has proven to be beneficial in the treatment of heart failure.

Summary

MSC Exosomes appear to be leading candidates to treat myocardial infarction and subsequent heart failure by carrying rich cargo from their parental cells. However, more clinical and pre-clinical studies on MSC exosomes will be required to confirm the beneficial effect to treat cardiovascular diseases
Literatur
1.
Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982–3021.PubMedPubMedCentralCrossRef
2.
Thej C, Kishore R. Unfathomed nanomessages to the heart: translational implications of stem cell-derived, progenitor cell exosomes in cardiac repair and regeneration. Cells. 2021;10(7).
3.
Joladarashi D, Garikipati VNS, Thandavarayan RA, Verma SK, Mackie AR, Khan M, Gumpert AM, Bhimaraj A, Youker KA, Uribe C, et al. Enhanced cardiac regenerative ability of stem cells after ischemia-reperfusion injury: role of human CD34+ cells deficient in microRNA-377. J Am Coll Cardiol. 2015;66(20):2214–26.PubMedPubMedCentralCrossRef
4.
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, et al. Heart Disease and Stroke Statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–528.PubMedCrossRef
5.
Karbasiafshar C, Sellke FW, Abid MR. Mesenchymal stem cell-derived extracellular vesicles in the failing heart: past, present, and future. Am J Physiol Heart Circ Physiol. 2021;320(5):H1999–2010.PubMedCrossRef
6.
7.
Dzobo K, Thomford NE, Senthebane DA, Shipanga H, Rowe A, Dandara C, Pillay M, Motaung K. Advances in regenerative medicine and tissue engineering: innovation and transformation of medicine. Stem Cells Int. 2018;2018:2495848.PubMedPubMedCentralCrossRef
8.
Potena L, Zuckermann A, Barberini F, Aliabadi-Zuckermann A. Complications of cardiac transplantation. Curr Cardiol Rep. 2018;20(9):73.PubMedCrossRef
9.
Hade MD, Suire CN, Suo Z. Mesenchymal stem cell-derived exosomes: applications in regenerative medicine. Cells. 2021;10(8).
10.
Fijany A, Sayadi LR, Khoshab N, Banyard DA, Shaterian A, Alexander M, Lakey JRT, Paydar KZ, Evans GRD, Widgerow AD. Mesenchymal stem cell dysfunction in diabetes. Mol Biol Rep. 2019;46(1):1459–75.PubMedCrossRef
11.
Tan SJO, Floriano JF, Nicastro L, Emanueli C, Catapano F. Novel applications of mesenchymal stem cell-derived exosomes for myocardial infarction therapeutics. Biomolecules. 2020;10(5).
12.
Schaefer A, Zwadlo C, Fuchs M, Meyer GP, Lippolt P, Wollert KC, Drexler H. Long-term effects of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: 5-year results from the randomized-controlled BOOST trial–an echocardiographic study. Eur J Echocardiogr. 2010;11(2):165–71.PubMedCrossRef
13.
Weil BR, Suzuki G, Leiker MM, Fallavollita JA, Canty JM Jr. Comparative efficacy of intracoronary allogeneic mesenchymal stem cells and cardiosphere-derived cells in swine with hibernating myocardium. Circ Res. 2015;117(7):634–44.PubMedPubMedCentralCrossRef
14.
Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54(24):2277–86.PubMedPubMedCentralCrossRef
15.
Bartolucci J, Verdugo FJ, Gonzalez PL, Larrea RE, Abarzua E, Goset C, Rojo P, Palma I, Lamich R, Pedreros PA, et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD Trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]). Circ Res. 2017;121(10):1192–204.PubMedPubMedCentralCrossRef
16.
Guo Y, Yu Y, Hu S, Chen Y, Shen Z. The therapeutic potential of mesenchymal stem cells for cardiovascular diseases. Cell Death Dis. 2020;11(5):349.PubMedPubMedCentralCrossRef
17.
Davani S, Marandin A, Mersin N, Royer B, Kantelip B, Herve P, Etievent JP, Kantelip JP. Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model. Circulation. 2003;108 Suppl 1:II253–258.
18.
Shen M, Chen T. Mesenchymal stem cell-derived exosomes and their potential agents in hematological diseases. Oxid Med Cell Longev. 2021;2021:4539453.PubMedPubMedCentralCrossRef
19.
Yen BL, Yen ML, Wang LT, Liu KJ, Sytwu HK. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: gleaning insights for possible use in COVID-19. Stem Cells Transl Med. 2020;9(10):1163–73.PubMedPubMedCentralCrossRef
20.
Yu K, Zeng Z, Cheng S, Hu W, Gao C, Liu F, Chen J, Qian Y, Xu D, Zhao J, et al. TPP1 enhances the therapeutic effects of transplanted aged mesenchymal stem cells in infarcted hearts via the MRE11/AKT pathway. Front Cell Dev Biol. 2020;8:588023.
21.
Jayaraman S, Gnanasampanthapandian D, Rajasingh J, Palaniyandi K. Stem cell-derived exosomes potential therapeutic roles in cardiovascular diseases. Front Cardiovasc Med. 2021;8:723236.
22.
Emanueli C, Shearn AI, Angelini GD, Sahoo S. Exosomes and exosomal miRNAs in cardiovascular protection and repair. Vascul Pharmacol. 2015;71:24–30.PubMedPubMedCentralCrossRef
23.
Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L, Buscher D, Fibbe W, Foussat A, Kwa M, et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies–bridging scientific observations and regulatory viewpoints. Cytotherapy. 2013;15(7):753–9.PubMedCrossRef
24.
Sun YQ, Zhang Y, Li X, Deng MX, Gao WX, Yao Y, Chiu SM, Liang X, Gao F, Chan CW, et al. Insensitivity of human iPS cells-derived mesenchymal stem cells to interferon-gamma-induced HLA expression potentiates repair efficiency of hind limb ischemia in immune humanized NOD Scid gamma mice. Stem Cells. 2015;33(12):3452–67.PubMedCrossRef
25.
Lai RC, Arslan F, Lee MM, Sze NS, Choo A, Chen TS, Salto-Tellez M, Timmers L, Lee CN, El Oakley RM, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010;4(3):214–22.PubMedCrossRef
26.
Joladarashi D, Thandavarayan RA, Babu SS, Krishnamurthy P. Small engine, big power: microRNAs as regulators of cardiac diseases and regeneration. Int J Mol Sci. 2014;15(9):15891–911.PubMedPubMedCentralCrossRef
27.
Meng H, Cheng W, Wang L, Chen S, Teng Y, Lu Z, Li Y, Zhao M. Mesenchymal stem cell exosomes in the treatment of myocardial infarction: a systematic review of preclinical in vivo studies. J Cardiovasc Transl Res. 2021.
28.
Wang N, Chen C, Yang D, Liao Q, Luo H, Wang X, Zhou F, Yang X, Yang J, Zeng C, et al. Mesenchymal stem cells-derived extracellular vesicles, via miR-210, improve infarcted cardiac function by promotion of angiogenesis. Biochim Biophys Acta Mol Basis Dis. 2017;1863(8):2085–92.PubMedCrossRef
29.
Ma T, Chen Y, Chen Y, Meng Q, Sun J, Shao L, Yu Y, Huang H, Hu Y, Yang Z, et al. MicroRNA-132, delivered by mesenchymal stem cell-derived exosomes, promote angiogenesis in myocardial infarction. Stem Cells Int. 2018;2018:3290372.PubMedPubMedCentralCrossRef
30.
•• Wang Z, Gao D, Wang S, Lin H, Wang Y, Xu W. Exosomal microRNA-1246 from human umbilical cord mesenchymal stem cells potentiates myocardial angiogenesis in chronic heart failure. Cell Biol Int. 2021;45(11):2211–2225. This reference indiactes that exosomal miR-1246 from human umbilical cord MSCs improves heart functions through increasing myocardial angiogenesis and reducing myocardial damagae by targeting PRSS23.
31.
Ma J, Zhao Y, Sun L, Sun X, Zhao X, Sun X, Qian H, Xu W, Zhu W. Exosomes derived from Akt-modified human umbilical cord mesenchymal stem cells improve cardiac regeneration and promote angiogenesis via activating platelet-derived growth factor D. Stem Cells Transl Med. 2017;6(1):51–9.PubMedCrossRef
32.
He JG, Li HR, Han JX, Li BB, Yan D, Li HY, Wang P, Luo Y. GATA-4-expressing mouse bone marrow mesenchymal stem cells improve cardiac function after myocardial infarction via secreted exosomes. Sci Rep. 2018;8(1):9047.PubMedPubMedCentralCrossRef
33.
• Huang P, Wang L, Li Q, Tian X, Xu J, Xu J, Xiong Y, Chen G, Qian H, Jin C, et al. Atorvastatin enhances the therapeutic efficacy of mesenchymal stem cells-derived exosomes in acute myocardial infarction via up-regulating long non-coding RNA H19. Cardiovasc Res. 2020;116(2):353–367. This reference links cardioprotective role of exosomes obtained from Atorvastatin-pretreated MSC via upregulating lncRNA H19 in a rat model of acute myocardial infarction.
34.
Sun J, Shen H, Shao L, Teng X, Chen Y, Liu X, Yang Z, Shen Z. HIF-1alpha overexpression in mesenchymal stem cell-derived exosomes mediates cardioprotection in myocardial infarction by enhanced angiogenesis. Stem Cell Res Ther. 2020;11(1):373.PubMedPubMedCentralCrossRef
35.
Wang X, Chen Y, Zhao Z, Meng Q, Yu Y, Sun J, Yang Z, Chen Y, Li J, Ma T, et al. Engineered exosomes with ischemic myocardium-targeting peptide for targeted therapy in myocardial infarction. J Am Heart Assoc 2018;7(15):e008737.
36.
Potz BA, Scrimgeour LA, Pavlov VI, Sodha NR, Abid MR, Sellke FW. Extracellular vesicle injection improves myocardial function and increases angiogenesis in a swine model of chronic ischemia. J Am Heart Assoc. 2018;7(12).
37.
Scrimgeour LA, Potz BA, Aboul Gheit A, Shi G, Stanley M, Zhang Z, Sodha NR, Ahsan N, Abid MR, Sellke FW. Extracellular vesicles promote arteriogenesis in chronically ischemic myocardium in the setting of metabolic syndrome. J Am Heart Assoc 2019;8(15):e012617.
38.
Aboulgheit A, Potz BA, Scrimgeour LA, Karbasiafshar C, Shi G, Zhang Z, Machan JT, Schorl C, Brodsky AS, Braga K, et al. Effects of high fat versus normal diet on extracellular vesicle-induced angiogenesis in a swine model of chronic myocardial ischemia. J Am Heart Assoc. 2021;10(4):e017437.
39.
Hu J, Chen X, Li P, Lu X, Yan J, Tan H, Zhang C. Exosomes derived from human amniotic fluid mesenchymal stem cells alleviate cardiac fibrosis via enhancing angiogenesis in vivo and in vitro. Cardiovasc Diagn Ther. 2021;11(2):348–61.PubMedPubMedCentralCrossRef
40.
Han C, Zhou J, Liang C, Liu B, Pan X, Zhang Y, Wang Y, Yan B, Xie W, Liu F, et al. Human umbilical cord mesenchymal stem cell derived exosomes encapsulated in functional peptide hydrogels promote cardiac repair. Biomater Sci. 2019;7(7):2920–33.PubMedCrossRef
41.
Xu H, Wang Z, Liu L, Zhang B, Li B. Exosomes derived from adipose tissue, bone marrow, and umbilical cord blood for cardioprotection after myocardial infarction. J Cell Biochem. 2020;121(3):2089–102.PubMedCrossRef
42.
Zhang C, Lu X, Hu J, Li P, Yan J, Ling X, Xiao J. Bovine milk exosomes alleviate cardiac fibrosis via enhancing angiogenesis in vivo and in vitro. J Cardiovasc Transl Res. 2021.
43.
• Ning H, Chen H, Deng J, Xiao C, Xu M, Shan L, Yang C, Zhang Z. Exosomes secreted by FNDC5-BMMSCs protect myocardial infarction by anti-inflammation and macrophage polarization via NF-kappaB signaling pathway and Nrf2/HO-1 axis. Stem Cell Res Ther. 2021;12(1):519. Findings from this study suggest that FNDC5 overexpressed BM-MSC-exosomes improved cardiac functions by increasing M2 phenotype and decreasing myocardial apoptosis in a mouse model of MI.
44.
Shen D, He Z. Mesenchymal stem cell-derived exosomes regulate the polarization and inflammatory response of macrophages via miR-21-5p to promote repair after myocardial reperfusion injury. Ann Transl Med. 2021;9(16):1323.PubMedPubMedCentralCrossRef
45.
Wei Z, Qiao S, Zhao J, Liu Y, Li Q, Wei Z, Dai Q, Kang L, Xu B. miRNA-181a over-expression in mesenchymal stem cell-derived exosomes influenced inflammatory response after myocardial ischemia-reperfusion injury. Life Sci. 2019;232:116632.
46.
Chen Q, Liu Y, Ding X, Li Q, Qiu F, Wang M, Shen Z, Zheng H, Fu G. Bone marrow mesenchymal stem cell-secreted exosomes carrying microRNA-125b protect against myocardial ischemia reperfusion injury via targeting SIRT7. Mol Cell Biochem. 2020;465(1–2):103–14.PubMedCrossRef
47.
Huang L, Yang L, Ding Y, Jiang X, Xia Z, You Z. Human umbilical cord mesenchymal stem cells-derived exosomes transfers microRNA-19a to protect cardiomyocytes from acute myocardial infarction by targeting SOX6. Cell Cycle. 2020;19(3):339–53.PubMedPubMedCentralCrossRef
48.
Peng Y, Zhao JL, Peng ZY, Xu WF, Yu GL. Exosomal miR-25-3p from mesenchymal stem cells alleviates myocardial infarction by targeting pro-apoptotic proteins and EZH2. Cell Death Dis. 2020;11(5):317.PubMedPubMedCentralCrossRef
49.
Mao Q, Liang XL, Zhang CL, Pang YH, Lu YX. LncRNA KLF3-AS1 in human mesenchymal stem cell-derived exosomes ameliorates pyroptosis of cardiomyocytes and myocardial infarction through miR-138-5p/Sirt1 axis. Stem Cell Res Ther. 2019;10(1):393.PubMedPubMedCentralCrossRef
50.
Sun XH, Wang X, Zhang Y, Hui J. Exosomes of bone-marrow stromal cells inhibit cardiomyocyte apoptosis under ischemic and hypoxic conditions via miR-486-5p targeting the PTEN/PI3K/AKT signaling pathway. Thromb Res. 2019;177:23–32.PubMedCrossRef
51.
Zhang CS, Shao K, Liu CW, Li CJ, Yu BT. Hypoxic preconditioning BMSCs-exosomes inhibit cardiomyocyte apoptosis after acute myocardial infarction by upregulating microRNA-24. Eur Rev Med Pharmacol Sci. 2019;23(15):6691–9.PubMed
52.
Rai AK, Lee B, Hebbard C, Uchida S, Garikipati VNS. Decoding the complexity of circular RNAs in cardiovascular disease. Pharmacol Res. 2021;171:105766.
53.
Li Q, Jin Y, Ye X, Wang W, Deng G, Zhang X. Bone marrow mesenchymal stem cell-derived exosomal microRNA-133a restrains myocardial fibrosis and epithelial-mesenchymal transition in viral myocarditis rats through suppressing MAML1. Nanoscale Res Lett. 2021;16(1):111.PubMedPubMedCentralCrossRef
54.
Wang X, Bai L, Liu X, Shen W, Tian H, Liu W, Yu B. Cardiac microvascular functions improved by MSC-derived exosomes attenuate cardiac fibrosis after ischemia-reperfusion via PDGFR-beta modulation. Int J Cardiol. 2021.
55.
Wu Y, Peng W, Fang M, Wu M, Wu M. MSCs-derived extracellular vesicles carrying miR-212–5p alleviate myocardial infarction-induced cardiac fibrosis via NLRC5/VEGF/TGF-beta1/SMAD Axis. J Cardiovasc Transl Res. 2021.
56.
Kore RA, Wang X, Henson JC, Ding Z, Jamshidi-Parsian A, Mehta JL. Proteomic basis of modulation of postischemic fibrosis by MSC exosomes. Am J Physiol Regul Integr Comp Physiol. 2021;321(5):R639–54.PubMedCrossRef
57.
Li Y, Zhou J, Zhang O, Wu X, Guan X, Xue Y, Li S, Zhuang X, Zhou B, Miao G et al. Bone marrow mesenchymal stem cells-derived exosomal microRNA-185 represses ventricular remolding of mice with myocardial infarction by inhibiting SOCS2. Int Immunopharmacol. 2020;80:106156.
58.
Chen M, Chen J, Li C, Yu R, Chen W, Chen C. Improvement of cardiac function by mesenchymal stem cells derived extracellular vesicles through targeting miR-497/Smad7 axis. Aging (Albany NY). 2021;13(18):22276–85.CrossRef
59.
Zhu W, Sun L, Zhao P, Liu Y, Zhang J, Zhang Y, Hong Y, Zhu Y, Lu Y, Zhao W, et al. Macrophage migration inhibitory factor facilitates the therapeutic efficacy of mesenchymal stem cells derived exosomes in acute myocardial infarction through upregulating miR-133a-3p. J Nanobiotechnology. 2021;19(1):61.PubMedPubMedCentralCrossRef
60.
Pu L, Kong X, Li H, He X. Exosomes released from mesenchymal stem cells overexpressing microRNA-30e ameliorate heart failure in rats with myocardial infarction. Am J Transl Res. 2021;13(5):4007–25.PubMedPubMedCentral
61.
Tang J, Cui X, Zhang Z, Xu Y, Guo J, Soliman BG, Lu Y, Qin Z, Wang Q, Zhang H, et al. Injection-free delivery of MSC-derived extracellular vesicles for myocardial infarction therapeutics. Adv Healthc Mater. 2021:e2100312.
62.
Wang X, Zhu Y, Wu C, Liu W, He Y, Yang Q. Adipose-derived mesenchymal stem cells-derived exosomes carry microRNA-671 to alleviate myocardial infarction through inactivating the TGFBR2/Smad2 axis. Inflammation. 2021;44(5):1815–30.PubMedCrossRef
63.
Wu Z, Cheng S, Wang S, Li W, Liu J. BMSCs-derived exosomal microRNA-150–5p attenuates myocardial infarction in mice. Int Immunopharmacol. 2021;93:107389.
64.
Lai TC, Lee TL, Chang YC, Chen YC, Lin SR, Lin SW, Pu CM, Tsai JS, Chen YL. MicroRNA-221/222 mediates ADSC-exosome-induced cardioprotection against ischemia/reperfusion by targeting PUMA and ETS-1. Front Cell Dev Biol. 2020;8:569150.
65.
Liu X, Li X, Zhu W, Zhang Y, Hong Y, Liang X, Fan B, Zhao H, He H, Zhang F. Exosomes from mesenchymal stem cells overexpressing MIF enhance myocardial repair. J Cell Physiol. 2020;235(11):8010–22.PubMedCrossRef
66.
Sun L, Zhu W, Zhao P, Zhang J, Lu Y, Zhu Y, Zhao W, Liu Y, Chen Q, Zhang F. Down-regulated exosomal microRNA-221 - 3p derived from senescent mesenchymal stem cells impairs heart repair. Front Cell Dev Biol. 2020;8:263.PubMedPubMedCentralCrossRef
67.
Sun L, Zhu W, Zhao P, Wang Q, Fan B, Zhu Y, Lu Y, Chen Q, Zhang J, Zhang F. Long noncoding RNA UCA1 from hypoxia-conditioned hMSC-derived exosomes: a novel molecular target for cardioprotection through miR-873-5p/XIAP axis. Cell Death Dis. 2020;11(8):696.PubMedPubMedCentralCrossRef
68.
Charles CJ, Li RR, Yeung T, Mazlan SMI, Lai RC, de Kleijn DPV, Lim SK, Richards AM. Systemic mesenchymal stem cell-derived exosomes reduce myocardial infarct size: characterization with MRI in a porcine model. Front Cardiovasc Med. 2020:7:601990.
69.
Dong J, Liu J, Wen Y, Tobin SW, Zhang C, Zheng H, Huang Z, Feng Y, Zhang D, Liu S, et al. Down-regulation of Lnc-CYP7A1–1 rejuvenates aged human mesenchymal stem cells to improve their efficacy for heart repair through SYNE1. Front Cell Dev Biol. 2020;8:600304.
70.
Zhuang L, Xia W, Chen D, Ye Y, Hu T, Li S, Hou M. Exosomal LncRNA-NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p. J Nanobiotechnology. 2020;18(1):157.PubMedPubMedCentralCrossRef
71.
Zhang L, Zhu XY, Zhao Y, Eirin A, Liu L, Ferguson CM, Tang H, Lerman A, Lerman LO. Selective intrarenal delivery of mesenchymal stem cell-derived extracellular vesicles attenuates myocardial injury in experimental metabolic renovascular disease. Basic Res Cardiol. 2020;115(2):16.PubMedPubMedCentralCrossRef
72.
Shi Y, Yang Y, Guo Q, Gao Q, Ding Y, Wang H, Xu W, Yu B, Wang M, Zhao Y, et al. Exosomes derived from human umbilical cord mesenchymal stem cells promote fibroblast-to-myofibroblast differentiation in inflammatory environments and benefit cardioprotective effects. Stem Cells Dev. 2019;28(12):799–811.PubMedCrossRef
73.
Ni J, Liu X, Yin Y, Zhang P, Xu YW, Liu Z. Exosomes derived from TIMP2-modified human umbilical cord mesenchymal stem cells enhance the repair effect in rat model with myocardial infarction possibly by the Akt/Sfrp2 pathway. Oxid Med Cell Longev. 2019;2019:1958941.PubMedPubMedCentralCrossRef
74.
Huang P, Wang L, Li Q, Xu J, Xu J, Xiong Y, Chen G, Qian H, Jin C, Yu Y, et al. Combinatorial treatment of acute myocardial infarction using stem cells and their derived exosomes resulted in improved heart performance. Stem Cell Res Ther. 2019;10(1):300.PubMedPubMedCentralCrossRef
75.
Luther KM, Haar L, McGuinness M, Wang Y, Lynch Iv TL, Phan A, Song Y, Shen Z, Gardner G, Kuffel G, et al. Exosomal miR-21a-5p mediates cardioprotection by mesenchymal stem cells. J Mol Cell Cardiol. 2018;119:125–37.PubMedCrossRef
76.
Ju C, Shen Y, Ma G, Liu Y, Cai J, Kim IM, Weintraub NL, Liu N, Tang Y. Transplantation of cardiac mesenchymal stem cell-derived exosomes promotes repair in ischemic myocardium. J Cardiovasc Transl Res. 2018;11(5):420–8.PubMedPubMedCentralCrossRef
77.
Xiao C, Wang K, Xu Y, Hu H, Zhang N, Wang Y, Zhong Z, Zhao J, Li Q, Zhu D, et al. Transplanted Mesenchymal Stem Cells Reduce Autophagic Flux in Infarcted Hearts via the Exosomal Transfer of miR-125b. Circ Res. 2018;123(5):564–78.PubMedCrossRef
78.
Cui X, He Z, Liang Z, Chen Z, Wang H, Zhang J. Exosomes from adipose-derived mesenchymal stem cells protect the myocardium against ischemia/reperfusion injury through Wnt/beta-catenin signaling pathway. J Cardiovasc Pharmacol. 2017;70(4):225–31.PubMedPubMedCentralCrossRef
Metadaten
Titel
Mesenchymal Stromal Cell Exosomes in Cardiac Repair
verfasst von
Darukeshwara Joladarashi
Raj Kishore
Publikationsdatum
29.01.2022
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 4/2022
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-022-01660-1

Weitere Artikel der Ausgabe 4/2022

Current Cardiology Reports 4/2022 Zur Ausgabe

Peripheral Vascular Disease (WS Jones, Section Editor)

Contemporary Management of Abdominal Aortic Aneurysms

Nuclear Cardiology (V Dilsizian, Section Editor)

Strategies for Imaging Metabolic Remodeling of the Heart in Obesity and Heart Failure

Nuclear Cardiology (V Dilsizian, Section Editor)

Artificial Intelligence to Improve Risk Prediction with Nuclear Cardiac Studies

In Memoriam

In Memory of Kanishka Ratnayaka

Congenital Heart Disease (RA Krasuski and G Fleming, Section Editors)

MRI-Guided Cardiac Catheterization in Congenital Heart Disease: How to Get Started

Interventional Cardiology (SR Bailey and T Helmy, Section Editors)

Vascular Closure: the ABC’s

Neu im Fachgebiet Kardiologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Komplette Revaskularisation bei Infarkt: Neue Studie setzt ein Fragezeichen

24.04.2024 ACC 2024 Nachrichten

Eine FFR-gesteuerte komplette Revaskularisation war in einer Studie bei Patienten mit akutem Myokardinfarkt und koronarer Mehrgefäßerkrankung klinisch nicht wirksamer als eine alleinige Revaskularisation der Infarktarterie.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise